Hyundai ADM Bio

Hyundai ADM Bio is a South Korean clinical research organization (CRO) service company. According to Korean Wikipedia, the company was established on October 31, 2003 under the name ADM Korea (ADM코리아). It provides clinical trial outsourcing services, a segment of the life-sciences and pharmaceutical services industry in South Korea. The company later changed its corporate name to Penetrium Bioscience (페니트리움바이오사이언스) in order to strengthen brand competitiveness and secure a foundation for sustained growth. The Korean Wikipedia entry states that the name change took place on March 6 of the same year in which the company reported a scientific breakthrough, and that in 2026 it announced a 73.9 billion won rights offering to the general public, with approximately 55 billion won (75%) of the proceeds intended for research and development, including Phase 1 clinical trials in domestic solid tumors (triple-negative breast cancer and non-small cell lung cancer), a Phase 2 dual-agnostic basket trial in the United States, and a Phase 2 clinical trial for rheumatoid arthritis. The company is also credited in the Korean Wikipedia entry with being the first in the world to elucidate the genetic mechanism for overcoming 'pseudo-resistance' — the idea that anticancer drug resistance arises from the physical barrier surrounding cancer cells rather than from genetic mutations in the cancer cells themselves. This positions the company at the intersection of clinical research services and oncology drug development. As of the available evidence, the company operates primarily in South Korea and maintains an official website at hdadmbio.com. Detailed information on ownership, executives, and financial listing status is not provided in the supplied sources.

Hyundai ADM Bio was established on October 31, 2003, under the name ADM Korea (ADM코리아) in South Korea. The company operates as a clinical research organization (CRO), providing outsourced clinical trial services to the pharmaceutical and biotechnology industry. In 2026, the company reported a significant scientific achievement: it claimed to be the first in the world to elucidate the genetic mechanism for overcoming 'pseudo-resistance' (가짜 내성), a concept holding that anticancer drug resistance is driven by the physical barrier surrounding cancer cells rather than by genetic mutations within the cancer cells themselves. This research positions the company in the oncology therapeutic space. On March 6 of the same year, the company changed its corporate name to Penetrium Bioscience (페니트리움바이오사이언스), stating that the rebranding was intended to strengthen brand competitiveness and secure a foundation for sustained growth. In May 2026, the company announced a 73.9 billion won rights offering to the general public. Of the proceeds, approximately 55 billion won (75%) was earmarked for research and development, including Phase 1 clinical trials for domestic solid tumors (triple-negative breast cancer and non-small cell lung cancer), a Phase 2 dual-agnostic basket trial in the United States, and a Phase 2 clinical trial for rheumatoid arthritis. The company maintains an official website at hdadmbio.com. Further details on its ownership structure, executive leadership, and financial listing status are not available in the supplied evidence.

• Company founded as ADM Korea (ADM코리아) in South Korea.

• Corporate name changed to Penetrium Bioscience (페니트리움바이오사이언스) to strengthen brand competitiveness.

• Announced 73.9 billion won rights offering, with 75% allocated to R&D including oncology and rheumatoid arthritis trials.

South Korean clinical research organization (CRO) with a focus on oncology and immunology clinical trials.

• Clinical trial outsourcing services

  Contract research organization services for pharmaceutical and biotechnology clients.

1. 1Wikidata entry for Hyundai ADM Biowikidata.org
2. 2페니트리움바이오사이언스 - Korean Wikipediako.wikipedia.org